



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Agmatine-Containing Poly(amidoamine)s as a Novel Class of Antiviral Macromolecules: Structural Properties and In Vitro Evaluation of Infectivity Inhibition

This is the author's manuscript

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/148664 since 2017-05-31T10:42:59Z

Published version:

DOI:10.1128/AAC.03420-14

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Antimicrob Agents Chemother. 2014 Oct;58(10):6315-9.

doi: 10.1128/AAC.03420-14.

The definitive version is available at:

http://aac.asm.org/

1	Agmatine-containing	g poly(amidoamine)s as novel class of antiviral macromolecules:
2	structural p	roperties and in vitro evaluation of infectivity inhibition
3	Manuela Donalisio ¹ , El	isabetta Ranucci ² , Valeria Cagno ¹ , Andrea Civra ¹ , Amedea Manfredi ² ,
4	F	Roberta Cavalli ³ , Paolo Ferruti ² , David Lembo ^{1*}
5	¹ Dipartimento di Scienze Clin	niche e Biologiche, Università degli Studi di Torino, 10043 Orbassano, Torino, Italy;
6	² Dipartimento di Chimica Orga	nica e Industriale, Università degli Studi di Milano, 20133 Milano, Italy; ³ Dipartimento
7	di Scienza e Tecn	ologia del Farmaco, Università degli Studi di Torino, 10125 Torino, Italy
8		
9		
10		
10 11		Punning title: Antiviral properties of $\mathbf{P} \mathbf{A} \mathbf{A}$ s
11		Running the. Antivital properties of TAAs
12		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26 27 28 29 30 31 32 33 34	* Corresponding author:	Prof. David Lembo Department of Clinical and Biological Sciences University of Torino, Regione Gonzole, 10 10043, Orbassano, Turino, Italy Phone: +39 011 6705484 Fax: +39 011 2365484 E-mail: <u>david.lembo@unito.it</u>
35		

36 ABSTRACT

37

Poly(amidoamine)s (PAAs) are multifunctional *tert*-amine polymers endowed with high structural versatility. Here we report on the screening of a minilibrary of PAAs against a panel of viruses. The PAA AGMA1 showed antiviral activity against herpes simplex virus, human cytomegalovirus, human papillomavirus-16, and respiratory syncytial virus, but not against human rotavirus and vesicular stomatitis virus. The results suggest the contribution of both polycationic nature and side guanidine groups in imparting antiviral activity.

44

45 The development of antiviral molecules usually focuses on either preventing virus entry into the 46 host cell or inhibiting virus replication following host infection. The first strategy may be based on 47 antiviral polyanionic polymers capable of competitively blocking the interaction between viral 48 proteins and cell surface heparan sulfate proteoglycans (HSPGs), which are exploited as attachment 49 receptors by many viruses (1, 2, 3, 4). Notwithstanding the large number of studies demonstrating 50 their efficacy in preclinical models, polyanionic polymers somehow failed in clinical trials (5). 51 Unlike polyanions, polycationic polymers have been less investigated as antiviral compounds. In 52 principle, polycations could act as antivirals by electrostatically interacting either with the 53 negatively charged cell membrane or with the envelope of lipid-enveloped viruses, thus preventing 54 virus adsorption onto cell surfaces, or directly inactivating the virus particle. In this context, it was 55 shown that the cationic poly(acrylic ester) Eudragit E100, endowed with a membrane-destabilizing 56 activity, exerts antiviral activity against a panel of lipid-enveloped viruses (6, 7). Another study 57 demonstrated that polyethylenimine, a cationic polymer able to condense DNA and mediate gene 58 transfer into mammalian cells, inhibits infection by human cytomegalovirus (HCMV) and human 59 papillomavirus (HPV), a lipid-enveloped virus and a non-enveloped virus respectively (8).

Poly(amidoamine)s (PAAs) are multifunctional *tert*-amine polymers endowed with high structural
versatility, obtained by Michael polyaddition of amines and bis-acrylamides (9). The repeating units
of PAAs can be designed to be reminiscent of peptides. For instance, an amphoteric, prevailingly
cationic PAA named AGMA1 is a polymer mimic of *arg-gly-glu* peptide (RGD) (10, 11).

In the search of new antiviral compounds, a minilibrary of PAAs was screened against a panel of seven viruses, namely herpes simplex virus type 1 and 2 (HSV-1, HSV-2), HCMV, HPV-16, human respiratory syncytial virus (RSV), human rotavirus (HRV) and vesicular stomatitis virus (VSV) chosen as representatives of different virus characteristics such as presence or absence of lipid envelope, nature of genome (DNA or RNA) and HSPG dependency for virus attachment (12, 13, 14, 15, 16).

70 The minilibrary included three water-soluble PAAs, ISA1, ISA23 and AGMA1, whose structures

71 are reported in Figure 1. The copolymeric ISA1 (17), containing two randomly distributed repeating 72 units present in equal amounts, and the homopolymeric ISA 23 (17, 18) and AGMA1 (19) were 73 prepared as previously reported. AGMA1 fractions with different average molecular weights were 74 obtained by ultrafiltration against water using membranes with different nominal molecular weight 75 cut off, as previously described (20). ISA1, is weakly cationic, but ISA23 and AGMA1 are 76 amphoteric, with isoelectric points ~5.2 and ~10.3. As reported in Table 1, at pH 7.4, these PAAs 77 have, respectively, +0.55, -0.55 and +0.55 average charges per unit. For ISA1, the reported value 78 corresponds to the ionization degree of its ter-amine groups, no other ionizable groups being 79 present. For ISA23 and AGMA1, the reported figures correspond to the excess negative over 80 positive charges and vice-versa, that is, respectively, -1+0.45 and -1+1.55 per unit. Thus, at pH 7.4 81 the overall cationic charge of ISA1 and AGMA1 is superficially similar, but a deeper insight 82 reveals that their real charge distribution is different.

83 Antiviral assays were performed by infecting cell monolayers in presence of serial dilutions of 84 compounds for 2 hours at 37°C to generate dose-response curves and a selectivity profile of the 85 PAAs antiviral spectrum. The inocula were subsequently washed out and replaced with culture 86 medium containing the same concentration of compounds. The effect on HSV and VSV infections 87 was evaluated by a standard plaque reduction assay on pre-seeded Vero cells in 24-well plates (10 x 10⁴ cells) infecting with 300 pfu/well of clinical isolates of HSV-1 and HSV-2 (21), and Vesicular 88 89 stomatitis virus (VSV) serotype Indiana; after incubation for 24 hours (HSV-2 and VSV) or 48 90 hours (HSV-1) at 37°C in 5% CO₂, cells were fixed and stained with 0.1% crystal violet in 20% 91 ethanol and viral plaques were counted. The mean plaque count for each drug concentration was 92 expressed as a percentage of the mean plaque count of the control.

In HCMV and RSV inhibition assays, infected cells were fixed and subjected to virus-specific immunostaining as described previously (22, 23). In these assays, cells were pre-seeded at a density of 6 x 10^3 /well in 96-well plates. Hep-2 cells were infected with RSV strain A2 (60 pfu/well) 96 whereas HELF cells with HCMV strain AD169 (24 pfu/well). Three days (RSV) or five days
97 (HCMV) post-infection viral immunostained plaques were microscopically counted.

98 HPV inhibition assays were performed on preplated 293TT cells (2 x 10^4 /well in 96-well plates) 99 using HPV-16 SEAP (secreted alkaline phosphatase) pseudoviruses (PsV) at the final concentration 100 of 1 ng/ml L1; three days post infection the SEAP content in the clarified supernatant was 101 determined as previously described (24). Plasmids used for PsV production were kindly provided 102 by J. Schiller (NCI, Bethesda USA). Antiviral assays for rotavirus were carried out on preplated 103 MA104 cells (1 x 10^4 /well in 96-well plates) using human rotavirus strain Wa (200 pfu/well). After 104 16 hours, viral foci were determined by indirect immunostaining (24).

105 The end-points of the assays were the effective compound concentration that reduced the viral 106 plaque/focus formation or SEAP activity by 50% (EC₅₀) in comparison to the untreated control. F 107 test was used to compare $LogEC_{50}$ s and two-way analysis of variance to analyze the significance 108 between percentages of infection at the same doses of different compounds not able to generate 109 $EC_{50}s$. Values of p < 0.05 were considered statistically significant. The EC_{50} values and all 110 statistical analyses were calculated by using the program PRISM 4 (GraphPad Software, San Diego, 111 California, U.S.A.). Cell viability assays were performed on cells pre-seeded in 96-well plates 112 under identical culture conditions of antiviral assays (i.e. cell density and time of incubation with 113 compounds) using CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA). The 50% 114 cytotoxic concentrations (CC_{50}) were determined using Prism software and the selectivity index 115 (SI) was calculated by dividing the CC50 by the EC50 (21). All data were generated from duplicate 116 wells in at least three independent experiments. Heparin was included in the study as a positive 117 control being a known inhibitor of HSPG-dependent viruses (e.g. HSV-1, HSV-2, HCMV, RSV 118 and HPV-16) (25, 26, 27, 28). As expected, heparin blocked infection by HSPG-dependent viruses 119 but not that by VSV and HRV which are not dependent on HSPG (Table 2).

Data reported in Table 2 prompt the following observations. The PAA antiviral effect was not aconsequence of cytotoxicity, since none of the screened compounds significantly reduced cell

122 viability at any concentration tested (i.e. up to 300 μ g/ml); therefore their CC₅₀ values may be 123 considered to be higher than 300 μ g/mL in all the cell lines tested.

Polydisperse AGMA1 strongly inhibited infections by HSV-1, HSV-2, HCMV and HPV-16, generating dose response-curves with EC_{50} values of 3.04, 5.34, 0.76, 0.54 µg/mL respectively. Interestingly, AGMA1 was significantly more active than heparin against HSV-1 and HPV-16 infections, whereas was as active as heparin against HCMV infection (p < 0.05). By contrast, polydisperse AGMA1 was inactive against RSV, HRV and VSV.

To evaluate the influence of molecular weight on antiviral potency, three additional linear AGMA1 129 fractions were prepared, namely AGMA14 (\overline{M}_n 4500), AGMA17 (\overline{M}_n 7800) and AGMA120 (\overline{M}_n 130 131 20500) (Table 1). As depicted in Table 2, fractions with lower and higher molecular weights than 132 polydisperse AGMA1 (M_n 10100) maintained inhibitory activity against HSV-1, HSV-2, HCMV 133 and HPV-16 although to different extents. AGMA14 showed a stronger anti-HSV-1 activity than 134 that of heparin and all fractions were more active than heparin against HPV-16 infection (p < 0.05). 135 No statistically significant differences were observed between EC50 of heparin and EC50s of 136 AGMA14 against HSV-2 and HCMV infections and between EC50 of heparin and EC50 of 137 AGMA120 against HSV-1 infection.

Unlike polydisperse AGMA1, AGMA14, AGMA17 and AGMA120 were active also against RSV
with EC50 values of 8.87, 7.44, and 1.37 μg/mL respectively. Both polydisperse AGMA1 and
AGMA1 fractions failed to display any significant inhibitory effect against HRV and VSV. The
antiviral activity of AGMA1 seems not to be dependent on its molecular weight for HSV-1, HSV-2,
HCMV and HPV-16, instead there is a clear relationship between AGMA1 fractions' size and antiRSV potency. Explaining why polydisperse AGMA1 did not exert a detectable anti-RSV activity,
while all of the size fractions did, demands further investigation.

Polymers do not consist of a single molecular specie, but rather of families of homologous species differing for the number of repeating units. Therefore, it is considered inappropriate to adopt the molar concept describing their properties. Nevertheless, to compare activity across compounds, 148 Table 3 shows the EC₅₀ values of AGMA1 fractions and heparin expressed in terms of molarity 149 instead of µg/ml, considering the average molecular weight reported in Table 1. It was not possible 150 to convert the average molecular mass of polydisperse AGMA1 in terms of molar equivalents since 151 its molecular mass is not univocally defined. Interestingly, the relationship between AGMA1 152 fractions' size and anti-RSV potency, reported in text when data were expressed in terms of µg/ml, is preserved. Furthermore, AGMA17 and AGMA120 preserved a higher anti-HPV-16 activity than 153 154 that of heparin (p < 0.05). By contrast, the antiviral activity of AGMA1₄ in terms of molarity is 155 lower than that in terms of µg/ml: its activity is similar to that of heparin against HSV-1 and HPV-156 16 infections and is lower to that of heparin against HSV-2 and HCMV (p < 0.05). This behavior 157 might be ascribed to a more rigidity of the polymer with the lowest molecular weight. Being all the 158 polymers polyelectrolytes, it is necessary to take into account that the charge density markedly 159 affect the dynamic rheological properties, the flexibility and the chain entanglements. Increased 160 polymer charge density results in intermolecular electrostatic repulsion and increased polymer 161 solubility.

162 Next, to investigate whether the activity of AGMA1 was specifically due to the structure of its 163 repeating unit, the antiviral activity of ISA1 and ISA23 was assessed. Overall, whilst AGMA1 was 164 active against HSV-1, HSV-2, HCMV, RSV and HPV-16 infection, ISA1 was active only against 165 HCMV and RSV with a lower activity than that of heparin and was as active as heparin against 166 HPV-16 (p < 0.05). ISA23 was inactive in all cases. At pH 7.4, both AGMA1 and ISA1 are 167 positively charged, whereas ISA23 is negatively charged. It is known that polycationic polymers 168 establish ionic interactions with the cell surface HSPG (29, 30), a feature that may impart antiviral 169 activity to these compounds. This feature, along with the finding that the active PAAs have the 170 same antiviral activity spectrum as heparin, supports the hypothesis that PAAs may exert their 171 antiviral action, at least in part, by interacting with HSPG thus preventing virus attachment. 172 However, notwithstanding AGMA1 and ISA1 carry the same density of positive charges, i.e. + 173 0.55, AGMA1 showed a greater activity for HSV-1, HSV-2 and HPV-16. This could be due to the different real charge distribution on the macromolecules and to its side guanidine groups reinforcing membrane interactions, according to their well-known chaotropic properties (31). By contrast, the guanidine side group does not seem to be necessary for the anti-HCMV activity. Furthermore, a different chain entanglement might explain the different activity of AGMA1 in respect to RSV. Overall these results provide a starting point to tailor a macromolecule with enhanced antiviral activity against a selected virus. Future work will be focused on narrowing the molecular mass distribution of PAA samples to assist in preclinical development.

181 Studies are ongoing to elucidate the mechanism of action the active PAAs and their antiviral182 potential and biocompatibility profile in preclinical models.

- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191

192 ACKNOWLEDGEMENTS

This work was supported by a grant from "Ricerca finanziata dall'Università degli Studi di Torino(ex 60%) 2012" to DL.

195

196 197

- 198
- 199

200 **REFERENCES**

- 1. Spillmann D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie. 83:811-817.
- 202 2. Liu J, Thorp SC. 2002. Cell surface heparan sulfate and its roles in assisting viral
 203 infections. Med Res Rev. 22:1-25.
- Tiwari V, Maus E, Sigar IM, Ramsey KH, Shukla D. 2012. Role of heparan sulfate in
 sexually transmitted infections. Glycobiology 22:1402-1412.
- Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. 2009. Sulfated K5
 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral
 microbicides. Pharmacol Ther. 123:310-322.
- 209 5. Pirrone V, Wigdahl B, Krebs FC. 2011. The rise and fall of polyanionic inhibitors of the
 human immunodeficiency virus type 1. Antiviral Res. 90:168-182.
- Alasino RV, Ausar SF, Bianco ID, Castagna LF, Contigiani M, Beltramo DM. 2005.
 Amphipathic and membrane-destabilizing properties of the cationic acrylate polymer
 Eudragit E100. Macromol Biosci. 5:207-213.
- Alasino RV, Bianco ID, Vitali MS, Zarzur JA, Beltramo DM. 2007. Characterization of
 the inhibition of enveloped virus infectivity by the cationic acrylate polymer eudragit E100.
 Macromol Biosci. 7(9-10):1132-1138.
- Spoden GA, Besold K, Krauter S, Plachter B, Hanik N, Kilbinger AF, Lambert C,
 Florin L. 2012. Polyethylenimine is a strong inhibitor of human papillomavirus and
 cytomegalovirus infection. Antimicrob Agents Chemother. 56(1):75-82.
- 9. Ferruti P. 2013. Poly(amidoamine)s: Past, Present, and Perspectives. Journal of polymer
 science, part A: Polymer Chemistry 51:2319–2353.
- 222 10. Ferruti P, Franchini J, Bencini M, Ranucci E, Zara GP, Serpe L, Primo L, Cavalli R.
- 223 2007. Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic,
 224 nonhemolytic, and "stealthlike" DNA complexing agent and transfection promoter.
 225 Biomacromolecules 8(5):1498-1504.

- 226 11. Cavalli R, Bisazza A, Sessa R, Primo L, Fenili F, Manfredi A, Ranucci E, Ferruti P.
- 227 2010. Amphoteric agmatine containing polyamidoamines as carriers for plasmid DNA in
 228 vitro and in vivo delivery. Biomacromolecules 11(10):2667-2674.
- Roizman B, Knipe MM, Whitley RJ. 2007. p. 2501-2601. Herpes Simplex Viruses. *In* B.
 N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, Lippincott-Raven,
 Philadelphia, PA
- Lowy DR, Howley PM. 2001. Papillomaviruses. p. 2231-2264. *In* Fields BN, Knipe DM,
 Howley PM (ed.) Fields Virology, Lippincott-Raven, Philadelphia, PA.
- Collins PL, Crowe JE Jr. 2007. Respiratory syncytial virus and Metaneumovirus. p 1601–
 1646. *In* Knipe DM, Howley PM (ed.) Fields Virology, 5th edition. Lippincott Williams and
 Wilkins, Philadelphia, PA
- Landolfo S, Gariglio M, Gribaudo G, Lembo D. 2003. The human cytomegalovirus.
 Pharmacol Ther. 98(3):269-297.
- 239 16. Cox E, Christenson JC. 2012. Rotavirus. Pediatr Rev. 33(10):439-445.
- Richardson S, Ferruti P, Duncan R. 1999. Poly(amidoamine)s as potential endosomolytic
 polymers: evaluation in vitro and body distribution in normal and tumour-bearing animals. J
 Drug Target. 6(6):391-404.
- 243 18. Ferruti P, Manzoni S, Richardson SCW, Duncan R, Patrick NG, Mendichi R, Casolaro
- M. 2000. Amphoteric linear poly(amido-amine)s as endosomolytic polymers: Correlation
 between physicochemical and biological properties. Macromolecules 33:7793-7800.
- 246 19. Ferruti P, Franchini J, Bencini M, Ranucci E, Zara GP, Serpe L, Primo L, Cavalli R.
- 247 2007. Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic,
 248 nonhemolytic, and "stealthlike" DNA complexing agent and transfection promoter.
 249 Biomacromolecules 8(5):1498-1504.

- 250 20. Cavalli R, Bisazza A, Sessa R, Primo L, Fenili F, Manfredi A, Ranucci E, Ferruti P.
 251 2010. Amphoteric agmatine containing polyamidoamines as carriers for plasmid DNA in
 252 vitro and in vivo delivery. Biomacromolecules 11(10):2667-2674.
- 253 21. Donalisio M, Nana HM, Ngono Ngane RA, Gatsing D, Tiabou Tchinda A, Rovito R,
- Cagno V, Cagliero C, Boyom FF, Rubiolo P, Bicchi C, Lembo D. 2013. In vitro antiHerpes simplex virus activity of crude extract of the roots of Nauclea latifolia Smith
 (Rubiaceae). BMC Complement Altern Med. 13(1):266.
- 257 22. Donalisio M, Rusnati M, Cagno V, Civra A, Bugatti A, Giuliani A, Pirri G, Volante M,
- Papotti M, Landolfo S, Lembo D. 2012. Inhibition of Human Respiratory Syncytial Virus
 Infectivity by a Dendrimeric Heparan Sulfate-Binding Peptide, Antimicrob. Agents.
 Chemother. 56: 5278-5288.
- 261 23. Funaro A, Gribaudo G, Luganini A, Ortolan E, Lo Buono N, Vicenzi E, Cassetta L,
- Landolfo S, Buick R, Falciola L, Murphy M, Garotta G, Malavasi F. 2008. Generation
 of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from
 immune B cells. BMC Biotechnol. 8:85.
- 265 24. Donalisio M, Rusnati M, Civra A, Bugatti A, Allemand D, Pirri G, Giuliani A,
 266 Landolfo S, Lembo D. 2010. Identification of a dendrimeric heparan sulfate-binding
 267 peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob
 268 Agents Chemother. 54(10):4290-4299.
- 269 25. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is
 270 binding to heparan sulphate. J. Virol. 63:52-58.
- 271 26. Kari B, Gehrz R. 1992. A human cytomegalovirus glycoprotein complex designated gC-II
 272 is a major heparin-binding component of the envelope. J Virol. 66(3):1761-1764.
- 273 27. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation
 274 requirements for respiratory syncytial virus infection. J.Virol. 74:10508 –10513.
- 275 28. Joyce JG, Tung J-S, Przysiecji CT, Cook JC, Lehman ED, Sands JA, Jansen KU,

276		Keller PM. 1999. The L1 major capside protein of human papillomavirus Type 11
277		recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans
278		on human keratinocytes. J. Biol. Chem. 274: 5810- 5822.
279	29.	Poon GM, Gariépy J. 2007. Cell-surface proteoglycans as molecular portals for cationic
280		peptide and polymer entry into cells. Biochem Soc Trans. 35 (4):788-793.
281	30.	Mislick KA, Baldeschwieler JD. 1996. Evidence for the role of proteoglycans in cation-
282		mediated gene transfer. Proc Natl Acad Sci U S A. 93(22):12349-12354.
283	31.	Myers JK, Pace CN, and Scholtz JM. 1995. Denaturant m values and heat capacity
284		changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci. 4:
285		2138–2148.
286		
287		
288		
289	FIGU	RE LEGENDS
290	Figure	e 1. Chemical structure of AGMA1, ISA1 and ISA 23 repeating units
291		



Figure 1. Chemical structure of AGMA1, ISA1 and ISA 23 repeating units

Polymer	\overline{M}_n	Net average charge per unit at pH 7.4	Average negative charges per unit at pH 7.4	Average positive charges per unit at pH 7.4
Polydisperse AGMA1	10100	+ 0.55	-1.00	+ 1.55
AGMA1 ₄	4500	+ 0.55	-1.00	+ 1.55
AGMA17	7800	+ 0.55	-1.00	+ 1.55
AGMA1 ₂₀	20500	+ 0.55	-1.00	+ 1.55
ISA1	13600	+ 0.55	0.0	+ 0.55
ISA23	16500	- 0.55	-1.00	+0.45

Table 1. Physico-chemical characteristics of PAAs

 \overline{M}_n = number average molecular weight. $\overline{M}_n = \frac{\sum_{i=1}^n N_i \times M_i}{\sum_{i=1}^n N_i}$, where N_i = number of macromolecules

containing *i* repeating units, and M_i = weight of macromolecules containing *i* repeating units.

Compounds	virus	EC ₅₀ (μg/ml) ^a (95% C.I.) ^b	CC ₅₀ (µg/ml) ^c	SI
AGMA1	HSV-1	3.04 (1.75 - 5.28)	> 300	> 98.7
	HSV-2	5.34 (1.85 - 15.4)	> 300	> 56.2
	HCMV	0.76 (0.40 -1.47)	> 300	> 395
	HPV-16	0.54 (0.53 - 0.55)	> 300	> 556
	RSV	> 100	> 300	n.a. ^d
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
AGMA14	HSV-1	1.93 (1.43 - 2.61)	> 300	> 155
-	HSV-2	1.35 (0.57 - 3.17)	> 300	> 222
	HCMV	0.39 (0.11 - 1.30)	> 300	>769
	HPV-16	0.92 (0.53 - 1.58)	> 300	> 326
	RSV	8.87 (6.51 - 12.1)	> 300	> 33.8
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
AGMA17	HSV-1	17.0 (11.4 - 25.4)	> 300	> 17.6
	HSV-2	4.80 (3.13 - 7.35)	> 300	> 62.5
	HCMV	4.45 (3.28 - 5.90)	> 300	> 67.4
	HPV-16	0.79 (0.44 - 1.44)	> 300	> 380
	RSV	7.44 (3.11 - 17.8)	> 300	> 40.3
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
AGMA1 ₂₀	HSV-1	5.10 (3.21 - 8.10)	> 300	> 58.8
	HSV-2	2.82 (1.72 - 4.64)	> 300	> 106
	HCMV	4.14 (2.50 - 6.86)	> 300	> 72.5
	HPV-16	0.72 (0.50 - 1.06)	> 300	> 417
	RSV	1.37 (1.11 - 1.68)	> 300	> 219
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
ISA1	HSV-1	> 100	> 300	n.a.
	HSV-2	> 100	> 300	n.a.
	HCMV	1.26 (0.79 - 2.00)	> 300	> 238
	HPV-16	3.55 (1.97 - 6.40)	> 300	> 84.5
	RSV	9.54 (5.51 - 16.5)	> 300	> 31.4
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
ISA23	HSV-1	> 100	> 300	n.a.
	HSV-2	> 100	> 300	n.a.
	HCMV	> 100	> 300	n.a.
	HPV-16	> 100	> 300	n.a.
	RSV	> 100	> 300	n.a.
	HRV	> 100	> 300	n.a.
	VSV	> 100	> 300	n.a.
Heparin	HSV-1	5.22 (4.22 - 6.45)	> 300	> 57.5
	HSV-2	0.67 (0.39 - 1.18)	> 300	> 448
	HCMV	0.38(0.24 - 0.64)	> 300	> /89
	HPV-10	2.88 (1.81 - 4.57)	> 300	> 104

Table 2. Antiviral activities of PAAs and heparin

RSV	0.05 (0.04 - 0.06)	> 300	> 6000
HRV	> 100	> 300	n.a.
VSV	> 100	> 300	n.a.

^a EC₅₀: 50% effective concentration

^b 95% CI: 95% confidence interval

^c CC₅₀: 50% cytotoxic concentration

^d n.a.: not assessable

Compounds	virus	EC ₅₀ (μM) ^a (95% C.I.) ^b	$\overline{CC_{50}(\mu M)^{\circ}}$
AGMA14	HSV-1	0.43 (0.30 – 0.61)	> 66.67
•	HSV-2	0.30(0.11 - 0.80)	> 66.67
	HCMV	0.33 (0.09 – 1.27)	> 66.67
	HPV-16	0.20 (0.12 - 0.33)	> 66.67
	RSV	1.97 (1.44 – 2.69)	> 66.67
	HRV	> 22.22	> 66.67
	VSV	> 22.22	> 66.67
AGMA17	HSV-1	2.18 (0.65 - 7.33)	> 38.46
	HSV-2	0.61(0.38 - 1.00)	> 38.46
	HCMV	0.56(0.41 - 0.76)	> 38.46
	HPV-16	0.10(0.06 - 0.18)	> 38.46
	RSV	0.95(0.40 - 2.28)	> 38.46
	HRV	> 12.82	> 38.46
	VSV	> 12.82	> 38.46
AGMA120	HSV-1	0.25(0.16 - 0.40)	> 14.63
	HSV-2	0.14(0.08 - 0.23)	> 14.63
	HCMV	0.20(0.12 - 0.33)	> 14.63
	HPV-16	0.04(0.02 - 0.51)	> 14.63
	RSV	0.07 (0.05 - 0.08)	> 14.63
	HRV	> 4.87	> 14.63
	VSV	> 4.87	> 14.63
Heparin	HSV-1	0.38(0.30 - 0.49)	> 21.90
-	HSV-2	0.04 (0.03 - 0.07)	> 21.90
	HCMV	0.03 (0.02 - 0.05)	> 21.90
	HPV-16	0.21 (0.13 – 0.36)	> 21.90
	RSV	0.01 (0.00 - 0.01)	> 21.90
	HRV	> 7.30	> 21.90

Table 3. Antiviral activities of Poly(amidoamine)s expressed in terms of approximate molar values

^a EC₅₀: 50% effective concentration

^b 95% CI: 95% confidence interval

^c CC₅₀: 50% cytotoxic concentration